A next-generation China-based clinical CRO with more than 350 staff who deliver to global quality standards. Led by a select team chosen from leading multinational biopharma firms, we are committed to helping companies leverage the clinical development and regulatory opportunities created by China’s radical regulatory liberalization and full ICH membership. We serve leading Western multinationals, innovative Chinese market leaders as well as emerging biotechs from both China and the West. Our serves can be delivered a project basis or as an end-to-end outsourcing partner for all clinical and regulatory needs.